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Abstract
Staphylococcus aureus is a pathogen of great importance to clinical and veterinary 
medicine. Recently, there has been a growing interest in S. aureus extracellular 
vesicles (EVs) in the pathogenesis of this bacterium. Released by living cells into the 
extracellular milieu, EVs are membranous structures carrying macromolecules such 
as proteins, nucleic acids, and metabolites. These structures play several physiologi-
cal roles and are, among others, considered a mechanism of intercellular communi-
cation within S. aureus populations but also in trans kingdom interactions. S. aureus 
EVs were shown to transport important bacterial survival and virulence factors, such 
as β-lactamases, toxins, and proteins associated with bacterial adherence to host 
cells, and to trigger the production of cytokines and promote tissue inflammation. In 
this chapter, we will review the main studies regarding S. aureus EVs, including their 
composition and roles in host-pathogen interactions, and the possible applications of 
EVs for vaccines and therapy development against staphylococcal infections.
Keywords: EV, membrane vesicles, composition, bacterial survival, cargo delivery, 
immunomodulation, host-pathogen interactions, immunization, vaccine, therapy
1. Introduction
1.1 EVs characteristics
The release of extracellular vesicles (EVs) is a long-known phenomenon widely 
reported, mainly in eukaryotes [1–4]. Archaea and Bacteria also release EVs, making 
their occurrence an evolutionally conserved feature among all three kingdoms [5]. 
They can be referred as membrane vesicles, microvesicles, ectosomes, exosomes, 
apoptotic bodies, outer membrane vesicles (OMVs), and others, depending on their 
origin and characteristics [5, 6]. The study of these particles is of great interest, 
as they are considered a mechanism of cell-free intercellular communication and 
trans kingdom interactions [7]. They are composed of a lipid bilayer and range from 
20 to 1000 nm. They carry several bioactive molecules, such as proteins, lipids, 
metabolites, and nucleic acids, and were shown to modulate the metabolism and 
physiology of local or distant target cells [8]. Recently, the study of bacterial EVs has 




1.2 History of bacterial EVs
The first study regarding bacterial EVs dates back to 1966, when lipid-like 
structures purified from culture supernatants of Escherichia coli were observed 
under electron microscopy [9]. In Gram-negative bacteria, vesiculation occurs from 
the budding out of the outer membrane (OM) that captures components present 
in the periplasm. This process forms nanoparticles called outer membrane vesicles 
(OMVs), which are released in the extracellular milieu [10]. Gram-positive bacteria 
lack an outer membrane and have a thicker peptidoglycan (PGN) cell wall, which 
was regarded as a barrier to EV release. This might explain why the first observa-
tions of EV release in Gram-positive bacteria were reported much later, in 2009, 
Figure 1. 
General features of S. aureus EVs.
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when Lee and collaborators demonstrated the production of EVs by Staphylococcus 
aureus [11]. Ever since, other studies confirmed EVs release by other Gram-positive 
bacteria belonging to various genera such as Bacillus sp, Bifidobacterium sp, 
Cutibacterium sp, Clostridium sp, Enterococcus sp, Lactobacillus sp, Mycobacterium sp, 
Propionibacterium sp, and Streptococcus sp, among others [12–22].
1.3 S. aureus and its derived EVs
S. aureus is a bacterium that asymptomatically colonizes the nasal track of 
20–80% of the human population without causing disease [23]. S. aureus is also a 
major opportunistic pathogen in humans, being a common cause of nosocomial 
infections [24]. It is a causative agent of life-threatening diseases such as sepsis, 
endocarditis, pneumonia, and minor infections in soft tissues [25]. S. aureus is also 
an important pathogen in veterinary medicine. It is one of the main etiological 
agents of mastitis, an inflammation of the mammary gland that affects dairy herds 
and causes vast economic losses worldwide [26]. The type and severity of infec-
tions depend on strain-specific virulence factors, mostly expressed from accessory 
genetic elements [27]. Secreted and surface-exposed S. aureus virulence factors are 
responsible for weakening the host immune response, immune evasion, damage to 
host tissues, and infection onset [28].
One emerging field of great interest is the involvement of EVs in the infections 
caused by S. aureus. Recent studies have shown that S. aureus EVs carry important 
bacterial survival and virulence factors, such as β-lactamases, superantigens, 
toxins, coagulases, and proteins associated with bacterial adherence to host cells 
[11, 29–34]. In some cases, they trigger production of cytokines and promote tissue 
inflammation [35–38]. As EVs are also regarded as potential vehicles for biotech-
nological and clinical applications, such as the development of vaccines [39–42], 
their study is an attractive area in microbiology and the future development of 
new strategies against bacterial infections. Here, we will address the main stud-
ies regarding S. aureus EVs, their biogenesis, composition, and roles in bacterial 
resistance, virulence, host-pathogen interactions, and the possible applications of 
EVs for diagnostic, therapy, and vaccine development against diseases caused by 
this bacterium (see Figure 1).
2. Biogenesis of bacterial EVs
Several models have been proposed to elucidate how bacteria release EVs. Since 
the study of Gram-negative bacteria OMVs dates to the ‘60s, this phenomenon is 
better established and documented. Several hypotheses are proposed to explain EVs 
production, which include one or a combination of many processes [43]. It has been 
proposed that the accumulation of molecules in the periplasm space alters turgor 
pressure, promoting OMV release [44, 45]. In another model, alterations in lipid 
structure and topology could lead to modifications in the membrane curvature, 
resulting in vesicle bubbling from the outer membrane [46]. On the contrary, EVs 
biogenesis is still poorly understood in Gram-positive bacteria [47] due to the recent 
discovery of EV release by these microorganisms [11]. Notably, efforts have been 
made to better understand how EVs can get through the thick PGN layer present in 
the Gram-positive bacteria’s cell wall structure.
In S. aureus, phenol-soluble modulins (PSMs) were shown to be associated 
with EVs release. These small proteins have surfactant-like properties and are 
Staphylococcus aureus
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considered crucial staphylococcal virulence factors since they can play various 
biological roles [48–50]. The staphylococcal PSMs were reported to have cytolytic 
and membrane-damaging activities, be proinflammatory, participate in biofilm 
formation, and be responsible for mobilizing lipoproteins from the staphylococcal 
cytoplasmic membrane, and the export of cytoplasmic proteins [51–55]. Since S. 
aureus EVs are generally enriched for both lipoproteins and cytoplasmic proteins, 
some studies investigated the role of PSMs in EV biogenesis. Wang et al. showed 
that deletion of psmα genes in S. aureus strain JE2 resulted in a significant decrease 
in size and number of EVs recovered from the culture supernatant [40]. Similarly, 
another study with strain USA300 revealed striking differences in EV production 
between the wild-type and a Δpsmα3 mutant [56], supporting a conserved process 
in S. aureus species. It was shown that PSMα3 promotes EVs release by an increase 
in membrane fluidity, and that bacterial turgor under hypotonic osmotic condi-
tions could be an important driving force for EV release in S. aureus [56]. Likewise, 
lipoproteins can also play a role in EV biogenesis since their absence resulted in 
an increase in membrane fluidity of S. aureus, as well as alterations in the protein 
content, the yield, and the size of EVs [57].
In addition to the importance of PSMs and lipoproteins in staphylococcal 
EV biogenesis, it was demonstrated that penicillin-binding proteins (PBPs) and 
autolysins also influence S. aureus EV release in acting likely on cell wall poros-
ity to allow EVs to cross the cell wall. PBPs are involved in PGN cross-linking, a 
crucial EV release factor [40]. The autolysins Atl and Sle1 are PGN hydrolases 
that play an important role in cell division, modifying, therefore, cell wall 
integrity. Accordingly, a pbp4 mutant, which was shown to significantly reduce 
PGN cross-linking [58], presents an increased EV production, whereas isogenic 
mutants for both Atl and Sle1 showed a significant decrease in EV size and 
release, consistent with their roles in peptidoglycan metabolism [40]. In another 
Gram-positive bacteria, B. subtilis, Toyofuku et al. evidenced that prophage-
encoded endolysins create holes in the PGN, allowing, therefore, the protrud-
ing of biological components to form EVs that are released in the extracellular 
environment [59].
3. S. aureus vesicle cargo composition
3.1 S. aureus vesicle protein cargo
Different molecules may be incorporated into EVs during their biogenesis: 
nucleic acids, proteins, lipids, and metabolites [5, 8, 60, 61]. Most studies on S. 
aureus EV cargo composition, however, focused mainly on their proteome. The 
first study characterizing the proteome of S. aureus EVs identified with high con-
fidence 90 proteins, distributed in cytoplasmic (56.7%), membrane (16.7%), and 
extracellular (23.3%) locations [11]. They included N-acetylmuramoyl-L-alanine 
amidase, which could have a predatory role in competing with other bacteria, 
transporters (SecD/SecF), and proteins related to antibiotic resistance, such as 
penicillin-binding proteins PBP1, PBP2 and PBP3, and β-lactamase [11]. They also 
found that S. aureus EVs comprise key virulence factors, such as superantigens 
(SSaA1 and SSaA2), toxins that disrupt host cell wall (α- and δ-hemolysins), 
coagulase factors, and immunomodulatory proteins, such as staphylococcal 
protein A (Spa), and immunoglobulin-binding protein (Sbi). Since then, several 
studies characterized the EV protein content of other S. aureus strains, reveal-
ing from 90 to 617 identified proteins, including numerous virulence factors 
(Table 1).
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Strain No. of 
proteins
Function Ref.
01ST93 Non-cytotoxic to host cells (Hep-2) [31]
03ST17 143 Non-cytotoxic to host cells (Hep-2, HaCaT) [31, 38]
Cytotoxic to host cells (HaCaT) [62]
Immunomodulation in vitro and in vivo (e.g., ↑ 
IL-1β, IL-6, IL-8, TNF-α, and MCP-1)
[38, 62]
Mast cell recruitment and exacerbation of skin 
inflammation
06ST1048 Cytotoxic to host cells (Hep-2) [29, 31]
143 Delivery of Spa protein through EVs (Hep-2) [29]
8325–4 Induction of the MAPK pathway (THP-1 and 
MLE-12)
[63]
Cytotoxicity to host cells (HeLa) [64]
Hemolytic activity [63, 64]
8325-4Δhla Low cytotoxic to host cells (HeLa) [64]
Weaker induction of MAPK pathway (THP-1 and 
MLE-12)
[63]
ATCC 14458 90 ND [11]
Cytotoxic to host cells (HaCaT) [30]
Immunomodulation in vivo (↑ IL-1β and IL-6, ↓ 
TNF-α)
Immunomodulation in vitro and in vivo (e.g., ↑ IL-6, 
INF-γ, MIP-1α, eotaxin)
[37]
Immunomodulation in vitro and in vivo (e.g., ↑ IL-6, 
TNF-α, IL-12, INF-γ)
[35]
Induce skin inflammation in mice [30, 37]
Promote lung inflammation in mice [35]
Protective against lung infections [42]
Transfer of resistance to β-lactams [32]
ATCC 25923 Cytotoxic to host cells (HaCaT) [65]
Immunomodulation in vitro (↑ IL-1β, IL-6, TNF-α, 
IL-8, and MCP-1)
Prevention of biofilm formation by other bacteria [66]
ATCC 6538 Non-cytotoxic to host cells (HDMECs) [36]
Induce recruitment of monocytes (THP-1)
Immunomodulation in vitro (e.g., ↑ E-selectin, 
ICAM1 and VCAM1, IL-6)
BWMR22 Exogenous EVs from vancomycin treated culture 
promote S. aureus aggregation
[67]
CI1449 Exogenous EVs confer bacterial resistance to whole 
blood killing
[68]
JE2 180 Cytotoxic to host cells (human leukocytes, THP-1 
cells, human macrophages MΦ)
[40, 57]











Decreased cytotoxicity and immunomodulation  
(THP-1 cells)
[57]
JE2-Δagr-Δspa 212 Non-cytotoxic to host cells 
(human leukocytes, A549, HL60, and rabbit 
erythrocytes)
[40]
Non-protective against lethal sepsis
JE2ΔagrΔspa 
pHlaH35L-LukE
Non-cytotoxic to host cells (human leukocytes, 
A549, HL60, and rabbit erythrocytes)
[40]
Protective against lethal sepsis
JE2Δlgt 198 Decreased cytotoxicity to host cells (human 
macrophages)
[57]
Defective in the induction of IL-1β, IL-18, and IL-6, 
and caspase-1 activation in vitro
M060 153 Cytotoxic to host cells (Hep-2, COS-7 and HaCaT) [31, 65]
153 Immunomodulation in vitro (↑ IL-1β, IL-6, TNF-α, 
IL-8, and MCP-1)
[65]
MSSA476 LB1: 131 BHI2: 
617
Exogenous EVs promotes bacterial survival 
ex vivo and in vivo (human whole blood and 
neutrophils)
[69]
MW2 168 ND [34]
N305* 222 Non-cytotoxic to host cells (PS and MAC-T) [33]
Immunomodulation in vitro and in vivo (e.g., ↑ IL-8, 
IL-1β, TNF-α, DEFβ1, MIP-2, BAFF)
Induction of neutrophil recruitment in vivo
ND [34]
Newman Immunomodulation in vitro (↑ IFN-β mRNA) [70]
O11* 164 ND [34]
O46* 171 ND [34]
RF122* 160 ND [34]
RN4220 92 ND [41]
RN4220 Δagr 119 Engineered EVs protect mice against viral  
infections
[41]
ST692 3: 137 4: 156 Transfer of resistance to β-lactams [71]
USA300 Immunomodulation in vivo (↑ IGM, total IgG, IgG1, 
IgG2a, and IgG2b)
[56]
Protective against systemic and skin infections [69]
Note: Production of EVs was also demonstrated for S. aureus strains ATCC 35556 [72], ATCC 700699 [29], NRS135 
[68], NRS77phage [68], RN4220phage [68], RN6390 [32], and TSST-1 103D [29], however, proteomic or functional 
characterization were not performed.*Animal isolates; ND, not determined.
1Luria-Bertani Medium.
2Brain Heart Infusion Medium.
3Optimal condition.
4Sub-inhibitory concentration of ampicillin.
Table 1. 
S. aureus-EVs characterization and functions.
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As shown in Table 1, S. aureus EVs comprise several proteins. The numbers of 
proteins vary from one study to another because of the proteomic approaches used 
and the growth conditions. Sometimes EV proteome comprises up to 24% of the 
whole bacterial predicted proteome. It is expected that different methods of protein 
detection may give divergent results, and, indeed, some studies have evidenced such 
variations. Lee et al. identified 41 and 84 proteins with In-gel and In-solution diges-
tion methods, respectively, with only 35 proteins shared by both sets of proteins 
identified [11]. In another study, Askarian et al. demonstrated that 43 and 286 
proteins are exclusively identified when using either In-solution and Lipid-Based 
Protein Immobilization (LPI) methods, respectively [69]. These results highlight 
the impact of detection methods for EVs characterization. Therefore, comparison 
of EVs produced by different S. aureus strains should be done carefully, like other 
comparative proteomic analysis.
In this regard, a recent study characterized and compared the proteome of EVs 
derived from several S. aureus strains using the same experimental approach [34]. 
This work was carried out on EVs produced by five S. aureus strains of diverse 
host origins (human, bovine, and ovine). A total of 253 proteins were identi-
fied (from 160 to 218 EV proteins according to the strain), 119 of which were 
common to EVs derived from all strains. This conserved EV proteome included 
several proteins related to nutrient uptake, antibiotic resistance, virulence, and 
pathogenesis, reinforcing the importance of EV cargo for bacterial survival and 
staphylococcal infections [34]. Numerous of these core EV proteins are also 
present within EVs produced by phylogenetically distant species supporting the 
existence of specific and conserved rules for protein loading into EVs that remain 
to be uncovered [34].
3.2 Selective protein cargo sorting into EVs
Since EVs bud out of the cytoplasmic membrane, it is natural that their composi-
tion mainly reflects the physiological state of the producing cells, as it has been 
shown by several studies characterizing the EV cargo [73, 74]. However, several 
studies showed strong evidence that protein cargo sorting is a selective regulated 
process in both Gram-negative and Gram-positive bacteria [8, 34, 75, 76]. As men-
tioned before, OMV biogenesis involves the capture of components associated with 
the periplasm and the OM. Interestingly, OMVs derived from Serratia marcescens 
lack proteins abundant in the OM and, in contrast, can be enriched with proteins 
that are absent in this compartment [77]. As another example, Porphyromonas gingi-
valis OMVs also exclude proteins abundant in the OM and are enriched with several 
virulence factors [78]. Regarding Gram-positive bacteria, studies demonstrated 
that the non-pathogenic B. subtilis secretes EVs enriched with lipoproteins and 
siderophore-binding proteins, which are essential to survival [13]. Mycobacterium 
bovis and Mycobacterium tuberculosis were also shown to be enriched with several 
lipoproteins, some of which can modulate the host response in a TLR2-dependent 
fashion, contributing to mycobacterial virulence [21].
Several studies demonstrated that S. aureus EV cargo comprises secreted, cell 
wall-anchored, membrane, and cytoplasmic proteins. The latter are their most 
abundant component [11, 33, 34, 69]. This feature is interesting since it is the 
unique known pathway of a Gram-positive bacteria to secrete cytoplasmic pro-
teins, which lack any export signals. Moreover, compared to whole-cell proteome, 
S. aureus EVs were also enriched with virulence-factors, extracellular proteins, 
and lipoproteins [11, 34]. For instance, Lee et al. demonstrated that Sbi is highly 
enriched in S. aureus EVs and is localized at the vesicle surface, enhancing its ability 
Staphylococcus aureus
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to bind to host cells [11]. Furthermore, secreted virulence factors such as coagu-
lases, β-lactamase, and hemolysins were also enriched [11]. Finally, comparative 
proteomics revealed that lipoproteins of five S. aureus clinical and animal isolates 
accounted for approximately 20% of the EV content, while they corresponded to 
only 2.5% of the whole predicted proteome [34]. These data show that some protein 
populations are enriched in S. aureus EVs, and they reinforce the hypothesis that 
the selection of protein cargo occurs through a dynamic mechanism common to 
the strains of S. aureus species. To date, the molecular mechanisms that drive the 
recruitment of proteins into EVs remain unclear. Nevertheless, it was proposed 
that abundance, charge, and subcellular location of proteins could influence their 
 availability and packing into S. aureus EVs [34].
3.3 S. aureus vesicle cargo: other components
As mentioned earlier, data regarding the characterization of the other compo-
nents of staphylococcal EVs apart from proteins are scarce. Although some studies 
demonstrated that lipids, carbohydrates, or nucleic acids are also associated with 
S. aureus EVs, they did not perform an extensive characterization of these compo-
nents. Schlatterer et al. used a fluorescent membrane dye (FM4–64) to quantify lip-
ids present in the membrane of S. aureus-derived EVs and demonstrated that lipid 
release is also dependent on PSMs [56]. In another study, the Fourier Transform 
InfraRed spectroscopy (FTIR) approach showed that administration of the antibi-
otic vancomycin induced chemical changes on S. aureus EVs, including the reduc-
tion of carbohydrate yield in comparison to untreated cells [67]. Regarding nucleic 
acids, in the study by Andreoni et al., quantification with PicoGreen dsDNA kit 
revealed the association of DNA molecules to S. aureus EVs [68]. Finally, Rodriguez 
and Kuehn recently demonstrated that S. aureus Newman strain secrets EVs con-
taining DNAs of ~500 base-pair long and RNAs with sizes of <300 nucleotides in 
length [70]. However, further investigations are necessary to better characterize the 
nucleic acid content of S. aureus EVs.
4. S. aureus-EVs functions
First considered “trash bags” to remove unwanted molecules from cells, nowa-
days, it is well-established that EVs play essential roles for bacterial fitness. Several 
described biological functions of OMVs and EVs include offensive and defensive 
mechanisms, such as quorum sensing, competition, delivery of toxins, resistance 
to antibiotics, horizontal DNA transfer, and transfer of regulatory RNAs (sRNAs), 
which can hijack the host immune response altering host-pathogen  interactions. 
S aureus EVs were shown to participate in several metabolic and infectious 
 processes, exhibiting several functions (Table 1).
4.1 S. aureus-EVs in cell toxicity
Studies demonstrated that S. aureus EVs can be cytotoxic and can induce cell 
death by delivering their toxin content. For example, δ-hemolysin (hld) and 
the exfoliative toxin A (ETA) were shown to be delivered to HEp-2 cells, induc-
ing cytotoxicity [31]. Moreover, exposition of human macrophages THP-1 to 
S. aureus JE2 EVs during 24 h also occasioned significant cellular cytotoxicity, a 
result that was sharply decreased when EVs were isolated from mutant lacking 
several pore-forming toxins (PFTs) [57]. In another study, Thay et al. showed 
9
Extracellular Vesicles and Their Role in Staphylococcus aureus Resistance and Virulence
DOI: http://dx.doi.org/10.5772/intechopen.96023
that S. aureus EVs contributed to HeLa cell cytotoxicity and erythrocyte lysis in a 
dose-dependent manner [64]. These results were tightly associated with biologi-
cally active α-hemolysin within EVs since their cytolytic and cytotoxic effects were 
significantly attenuated when EVs were isolated from an isogenic hla mutant [64]. 
Furthermore, in vivo experiments conducted by Hong et al. revealed that only S. 
aureus EVs could disrupt the skin barrier and cause dermal inflammation, which 
was not observed in the presence of purified α-hemolysin or EVs from strains 
that lack this protein [30]. More interestingly, they showed that EV-associated 
α-hemolysin was more cytotoxic than the purified toxin itself, and while the 
first induced necrosis, soluble α-hemolysin induced apoptotic cell death [30]. 
Together, these findings highlight the critical role of EVs in host cell death during 
 staphylococcal toxicity.
4.2 S. aureus-EVs in antibiotic resistance and biofilm formation
Besides delivering toxins to host cells, S. aureus EVs were shown to play an 
important role in antibiotic resistance. Lee et al. demonstrated that biologically 
active BlaZ, a β-lactamase protein, is present inside S. aureus EVs [32]. EVs contain-
ing BlaZ were able to confer a transient resistance against ampicillin to susceptible 
surrounding Gram-negative and Gram-positive bacteria, including different strains 
of E. coli, Salmonella enterica serovar Enteritidis, Staphylococcus epidermidis, and 
S. aureus [32]. In a more recent report by Kim et al., the protective effect of EVs 
derived from the methicillin-resistant S. aureus (MRSA) strain ST692 grown in 
the presence of ampicillin was evaluated. Accordingly, ST692 EVs were shown to 
protect susceptible ATCC29213 strain against six different β-lactam antibiotics in 
a dose-dependent manner [71]. In another study, the addition of exogenous EVs 
purified from the culture supernatant of strain BWMR22 grown in the presence 
of a sub-inhibitory concentration of vancomycin was able to increase S. aureus 
adhesion and cell aggregation, contributing to biofilm formation [67]. Finally, it 
was shown that application of S. aureus EVs to polystyrene surfaces reduces biofilm 
formation by several other pathogenic bacteria, including Acinetobacter baumannii, 
Enterococcus faecium, and Klebsiella pneumonia [66]. This can be explained by the 
ability of S. aureus EVs to increase the hydrophilicity of surfaces, a key parameter 
for the initiation of biofilm formation [66]. This conversion of surface properties 
confers a vital competitive advantage that could explain the prevalence of S. aureus 
as a nosocomial pathogen.
4.3 S. aureus-EVs in immunomodulation
Various studies also demonstrated the role of S. aureus EVs on immunomodula-
tion and their contribution to the induction or exacerbation of pulmonary and 
skin inflammations. Detection of S. aureus EVs in house dust led Kim et al. to 
investigate their role in lung infection models. Repeated airway exposure of mice to 
these particles resulted in a local increase in cytokine production and neutrophilic 
pulmonary inflammation [35]. Regarding cutaneous infections, it was shown that 
S. aureus EVs induce atopic dermatitis (AD) inflammation by enhancing cutane-
ous production of various cytokines, which promote infiltration of the dermis by 
mast cells and eosinophils, and consequently the increase in epidermal thickening 
in mice [30, 37]. In addition to that, S. aureus EVs were also shown to exacerbate 
inflammation in an AD mouse model [38]. Topical application of S. aureus EVs 
resulted in severe eczematous dermatitis, skin thickening, and a massive infiltration 
by inflammatory and mast cells [38]. These symptoms were not observed when 
Staphylococcus aureus
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animals were treated with lysed EVs [38]. Finally, an in vitro study showed that 
human dermal microvascular endothelial cells exposed to S. aureus EVs produce 
cell adhesion molecules, such as E-selectin, ICAM1, and VCAM1, which efficiently 
promote endothelial cell activation and monocyte recruitment, contributing, 
therefore, to the infiltration of immune cells [36].
Wang et al. demonstrated that EVs derived from the S. aureus JE2 strain could 
activate TLR2 signaling of NLRP3 inflammasomes in human macrophages through 
K+ efflux and apoptosis-associated speck-like protein (ASC) recruitment [57]. 
ASC is a key adaptor complex required for caspase-1 activation, which leads to the 
release of the mature forms of IL-1β and IL-18 cytokines. They also investigated 
whether EVs derived from a mutant for the agr quorum-sensing system and the 
SaeRS two-component system could affect inflammasome activation since they 
control the release of several PFTs, such as hemolysins and leukocidins. Indeed, 
the ΔargΔsaeRS EVs packed a minimum amount of PFTs, leading to the absence of 
caspase-1 activation and a consequent decrease in the release of IL-1β and IL-18 
by human macrophages [57]. Similarly, a mutation in a gene involved in lipidation 
and maturation of lipoproteins (Δlgt) also decreased the levels of Hla and of the 
leukocidin LukS-PV present inside EVs, and, consequently, their ability to induce 
caspase-1 activation and cytokine release [57].
A recent study conducted by Rodriguez et al. demonstrated that nucleic acid 
associated with S. aureus EVs is immunomodulatory [70]. They identified DNA and 
RNA populations associated with EVs derived from Newman strain and provided 
evidence that these nucleic acids are delivered into host endosomal compart-
ments [70]. In vitro experiments showed that murine macrophages exposed to 
EVs presented a strong IFN-β mRNA expression after 3 hours of stimulation [70]. 
Pretreatment of macrophages with inhibitors of endosomal acidification strongly 
reduced IFN-ß mRNA expression after EV stimulation, suggesting that EVs’ 
processing depends on the acidic endosomal environment to release their immuno-
modulatory cargo and promote TLR signaling [70]. These results were corroborated 
when the exposition of TLR3−/−, TLR7−/−, and TLR9−/− mouse macrophages to 
EVs reflected in a substantial decrease in IFN-ß mRNA expression [70].
As described above, most studies regarding S. aureus EVs have focused mainly on 
clinical human isolates, and to date, there is only one report describing the biologi-
cal functions of EVs derived from a S. aureus animal strain. Tartaglia et al. demon-
strated that EVs derived from the bovine mastitis strain Newbould 305 carry several 
virulence factors and induce cytokine production in a bovine mammary epithelial 
cell in vitro without altering their viability [33]. Additionally, they showed that 
the intraductal inoculation of EVs in the mouse mammary gland promotes inflam-
mation, tissue deterioration, and cytokine and chemokine production in murine 
mammary glands [33]. Altogether, these data indicate that staphylococcal EVs can 
interact with and modulate host cells’ immune response, suggesting that EVs can 
play an important role in staphylococcal pathogenesis.
5. S. aureus-EVs delivery to host cells
5.1 S. aureus-EVs integrity and cell toxicity
Secretion of molecules and virulence factors is an essential component of 
S. aureus pathogenesis, including toxins, adhesins, and invasins. Molecules such 
as proteins or nucleic acids released in the surrounding medium may be rapidly 
degraded by the proteases or nucleases secreted in the extracellular milieu. The 
bilayered EVs thus appear as protective vehicles for efficient delivery of components 
11
Extracellular Vesicles and Their Role in Staphylococcus aureus Resistance and Virulence
DOI: http://dx.doi.org/10.5772/intechopen.96023
in a concentrated manner. Gurung et al. were the first to evidence that Spa delivery 
via EVs was responsible for host cell death only when EVs were intact, establishing 
S. aureus EVs as effective delivery vehicles to target cells [29].
Other studies confirmed this role of EVs. For instance, disrupted EVs produced 
by S. aureus ATCC 25923 strain were shown to be four times less cytotoxic than 
intact EVs [65]. Again, whole and lysed EVs derived from strain 03ST17 were both 
cytotoxic and proinflammatory, however, these properties were more intense when 
EVs were intact [38, 62]. Nevertheless, in some cases, EV integrity does not influ-
ence their cytotoxic properties, as it is the case of S. aureus M060 EVs, that in both 
intact and disrupted states had the same cytotoxicity levels towards HaCaT cells 
[65]. These results highlight that EVs’ integrity is essential and can lead to differ-
ent outcomes depending on the mode of action of the effector molecules and the 
mechanism of EV cargo delivery.
5.2 S. aureus-EVs internalization into host cells
As important as the transport of cargo by EVs is how they transfer their cargo to 
recipient cells. They can act extracellularly through ligand-receptor interactions or 
intracellularly after their internalization into target cells and cargo release [79]. In 
the latter case, EVs’ internalization may occur through several pathways, which all 
subsequently lead to an intracellular release of their cargo. These pathways include 
membrane fusion, phagocytosis, macropinocytosis, and lipid-raft-, caveolin- or 
clathrin-mediated endocytosis [80].
Studies showed that S. aureus EVs could interact with host cells via cholesterol-
rich membrane microdomain. The cholesterol-sequestering agent Filipin III 
prevents EV membrane fusion and cargo delivery into host cells [29, 64]. Another 
study demonstrated that of all pretreatments of human macrophages with different 
inhibitors for clathrin-, lipid raft-, actin-, and dynamin-dependent endocytosis, 
only dynasore inhibited the entry of EVs into host cells, suggesting that EV uptake 
is mediated by dynamin-mediated endocytosis [57]. This finding is supported by a 
recent report by Rodriguez et al., where macrophages exposed to S. aureus Newman 
EVs had a substantial decrease in IFN-β mRNA expression when cells were also pre-
treated with dynasore [70]. They also provided visual evidence through molecule 
labeling and confocal microscopy that EV-associated RNAs are efficiently delivered 
into macrophages [70]. Both membrane fusion and endocytosis depend on the 
integrity of EVs. This may explain why intact EVs usually present higher cytotoxic-
ity since they allow direct delivery of concentrated components into host cells, 
enhancing, therefore, cell damage and immunomodulation. Although these recent 
findings highlight the role of cholesterol-rich domains and dynamin in S. aureus EV 
uptake, one cannot exclude that staphylococcal EVs exploit diverse entry routes for 
their cargo delivery host cells.
6. S. aureus-EVs environmental modulation
6.1 Impact of growth conditions in S. aureus-EV release
Besides intrinsic bacterial factors, several external factors were also shown to 
modify EV production. In S. aureus, exposure to the antibiotic penicillin signifi-
cantly increased EV number, size, and protein yield compared to untreated bacte-
rial cultures. In contrast, treatment with the antibiotic erythromycin did not affect 
EVs release [40]. This can be explained by the nature of each antibiotic action with 
penicillin affecting cell wall biosynthesis, whereas erythromycin is active on protein 
Staphylococcus aureus
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translation. Likewise, in another study, S. aureus had a significant increase in EVs 
release after exposure to the β-lactam antibiotics flucloxacillin and ceftaroline 
due to their ability to weaken the PGN wall [68]. Again, addition of the β-lactam 
ampicillin increased S. aureus EV production in a dose-dependent manner, which 
corresponded to a 22.4-fold increase at 64 μg/mL concentration [71]. The PGN 
present in the bacterial cell wall of most bacteria has a rigid structure formed of 
highly cross-linked polymers composed of polysaccharide chains and short peptides 
[81]. β-Lactams have been shown to decrease PGN cross-linking by serving as a 
substrate that irreversible binds and inactivates a transpeptidase involved in cell 
wall biosynthesis. As a result, it increases cell wall permeability due to the presence 
of a looser PGN matrix structure, allowing vesicles to cross the cell wall with less 
resistance, generating, therefore, particles in higher numbers and sizes. The cor-
relation between vesicle release and PGN cross-linking has also been reported for 
Gram-negative bacteria [10, 82].
6.2 Impact of growth conditions in S. aureus-EV cargo composition
Culture conditions also alter EV content since bacteria modulate gene expression 
and protein secretion to cope with environmental changes. Indeed, comparative 
proteomic analysis revealed that 131 and 617 proteins were identified in EVs derived 
from S. aureus strain MSSA476 grown in Luria-Bertani (LB) and Brain-Heart 
Infusion (BHI) broth, respectively, with 109 proteins identified in both condi-
tions [69]. Moreover, EVs derived from LB cultures were two-fold larger than 
those derived from BHI cultures, even though the latter presented higher protein 
diversity, which may also explain their significantly higher cytotoxicity towards 
neutrophils following brief exposure compared to LB-derived EVs [69]. In another 
study, proteomics identified 156 and 137 proteins in EVs derived from cultures in 
the presence and absence of a sub-inhibitory concentration of ampicillin, respec-
tively, while only 67 proteins were shared by both conditions [71]. Another example 
of changes in EVs content was observed in the chemical composition of S. aureus 
EVs following treatment with vancomycin at 1 mg/ml. Compared to EVs produced 
by untreated bacteria, EVs prepared from vancomycin-treated cultures presented 
an increase in the ratio of protein relative to carbohydrates [67].
Additionally, EV content can also be impacted by a combination of several fac-
tors. For instance, Andreoni et al. evidenced that EVs produced by lysogenic strains 
had a significantly higher amount of DNA than those of the cured strains when a 
DNA-damaging SOS antibiotic was used, while the DNA content was unchanged 
in EVs purified from cultures treated with β-lactam [68]. This can be explained by 
the prophage-induced cell lysis caused by SOS-response triggering components, 
leading to an increase of DNA inside EVs, which does not occur with β-lactams 
since they target bacterial cell wall biosynthesis. These findings evidence that both 
intrinsic and external factors impact EV release and content, but much research is 
necessary to better elucidate EV biogenesis and cargo selection in S. aureus as well as 
in other bacteria.
7. S. aureus-EVs and host cells specificity
7.1 S. aureus-EVs strain specificity
Cytotoxicity and immunomodulation of EVs towards host cells vary accord-
ing to the S. aureus strain and host cell line studied since both can have specific 
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characteristics. As virulence factors vary from an S. aureus strain to another, so does 
the cargo of EVs. This affects cytotoxicity and host cell response to EVs contact. 
It was demonstrated that the presence of α-hemolysin in EVs is directly related to 
host cell death, and EVs from α-hemolysin-negative strains have very low or no 
cytotoxic effect on different cell types [30, 64]. Similarly, EVs from M060 S. aureus 
strain containing exfoliative toxin A (ETA) were highly cytotoxic towards HEp-2 
cells, contrary to EVs purified from three other S. aureus isolates that lacked the ETA 
protein [31]. Furthermore, it was also demonstrated that EVs from S. aureus ATCC 
25923 induces a stronger immune response in HaCaT cells than that of M060 EVs 
at the same concentrations [65]. These data show that EVs from different S. aureus 
strains indeed have different effects on host cells.
7.2 Host cell lines specificity
On the other hand, the cell lines used in vitro also have different responses 
reflecting differences in host cells-EVs interactions, which result in variable 
cytotoxicity, and immunomodulation levels. EVs derived from S. aureus subsp. 
aureus Rosenbach MSSA476 induced extensive cell death in human neutrophils and 
THP-1 cells, while it had very low cytotoxicity in HaCaT at the same concentra-
tions [69]. In another study, S. aureus JE2 EVs were showed to be less cytotoxic to 
airway epithelial cells (A549) than to erythrocytes and neutrophil-like HL60 cells 
[40]. As another example, after exposure to ATCC 14458 S. aureus EVs, alveolar 
macrophages produced TNF-α and IL-6, while A549 cells produced only IL-6 
[35]. Together, these findings show that EVs’ role in host cell toxicity and immune 
response is strongly affected by the variations in EV cargo, which itself vary from 
an S. aureus strains to another, and to variations in molecular and physiological 
characteristics of the host cell types.
8. Applications of bacterial EVs
8.1 Use of EVs as a vaccine platform
As reviewed above, EVs interact with host cells leading to cytotoxicity, 
immunomodulation, tissue disruption, and other effects that mimic those caused 
by living bacteria during infection. These characteristics make EVs interesting 
vectors for delivering antigens and other components, some of which may have 
adjuvant properties. These features make EVs good candidates for vaccine devel-
opment. Several studies have shown that EVs can induce adaptive immunity and 
confer protection against infections caused by both Gram-negative and Gram-
positive pathogenic bacteria [83–85]. For instance, mice immunized with 1 μg of 
E. coli derived OMVs resulted in 100% protection against a lethal dose challenge, 
while the survival rate was only 20% in the untreated group [86]. In another 
study, intraperitoneal administration of Streptococcus pneumoniae BAA-255 EVs 
protected mice against the EV-producing cells and the pathogenic KCCM-41569 
strain, demonstrating EVs’ ability in eliciting a cross-protection against different 
strains [14].
8.2 Use of EVs against S. aureus infections
Regarding S. aureus, several studies have already reported the use of its derived 
EVs for immunization, revealing its potential in vaccine design. In 2015, Choi et al. 
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demonstrated that exposition of bone marrow-derived dendritic cells to ATCC 
14458 EVs during 24 h enhanced the expression of co-stimulatory molecules CD80 
and CD86 and of proinflammatory mediators such as TNF-α, IL-6, and IL-12, 
suggesting the induction of adaptive immunity [42]. As expected, intramuscular 
administration with three doses of >5 μg of ATCC 14458 EVs resulted in 100% 
protection against challenge with a lethal dose of bacteria in a mouse pneumonia 
model, with a reduction of bacterial colonization, pneumonia, and production of 
cytokines [42]. They revealed that immunization is mediated mainly by CD4+ T cell 
response, and transfection of these cells from EVs-immunized mice to naïve mice 
results in 70% protection after a lethal-dose challenge of S. aureus. Finally, they 
demonstrated that ATCC 14458 EV immunization provides long-term protective 
immunity and that it is a safe method since the administration of EV doses 10-fold 
higher were not cytotoxic to mice [42].
In another study, Askarian et al. demonstrated that intraperitoneal vaccina-
tion with USA300-derived EVs promoted a high production of antibodies, in 
addition to the protection of mice against subcutaneous and systemic S. aureus 
infections [69]. Another example of S. aureus EVs’ application as a vaccine was 
shown by Wang et al. EVs were purified from the JE2 ΔagrΔspa strain contain-
ing a plasmid coding for non-toxic Hla and LukE toxins under control of the spa 
promoter, whose activity is enhanced in the absence of the arg quorum sensing 
system [40]. They demonstrated that recombinant non-toxic Hla and LukE are 
immunogenic, and engineered EVs carrying these detoxified cytolysins protected 
mice against lethal sepsis infection [40]. Remarkably, reports on OMVs used as 
vaccine platforms against S. aureus infections were also explored. Irene et al. used 
OMVs derived from E. coli to incorporate five S. aureus antigens, Hla, SpA, FhuD2, 
Csa1, and LukE. They were successfully integrated into E. coli OMVs, correspond-
ing from 5–20% of the total protein content [87]. The engineered OMVs conferred 
significant protection against sepsis, kidney, and skin S. aureus experimental 
infections in mice [87].
8.3 Use S. aureus-EVs against other infections
Interestingly, Yuan et al. used EVs derived from the S. aureus RN4220-Δagr 
strain to produce particles with a reduced content of virulence factors and a 
decreased toxicity to generate a safe platform against viral infections [41]. Major 
components of S. aureus EVs were fused to tag sequences able to incorporate viral 
antigens, generating PdhB-FLAG and Eno-FLAG proteins associated with enve-
lope E domain III, the primary protective domain for prevention of dengue virus 
(DENV) [41]. These heterologous viral antigens were successfully integrated into 
EVs, which induced antibodies against four DENV serotypes and protected mice 
against lethal challenge with DENV-2 [41].
9. Conclusions
As addressed here, EVs transport various types of biomolecules that have 
been reportedly associated with bacterial survival and host-pathogen interac-
tions. S. aureus is, to date, one of the best-documented bacteria in this field. Yet, 
several research questions remain to be elucidated. First, EVs biogenesis is still 
poorly understood in Gram-positive bacteria even though recent studies showed 
S. aureus-EVs biogenesis can be affected by a range of intrinsic and external fac-
tors, such as PSMs, autolysins, and environmental conditions, such as antibiotics. 
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Moreover, several studies evidenced that selective cargo sorting exist. Since the 
EV cargo determines their biological functions, clarifying which components are 
selected, and how, is of crucial value to understand their role in pathogenesis, 
and to their use as delivery systems. Second, most studies on S. aureus EVs have 
focused on proteomes. As well as proteins, nucleic acid cargo could play essential 
roles in S. aureus survival and pathogenesis. They could be associated to horizontal 
gene transfer for antibiotic resistance, and regulation of host cell expression by 
small regulatory RNAs. Therefore, more research is necessary in this field. Third, 
the physiological role of S. aureus EVs remains elusive. Staphylococcal EV cargo 
was shown to induce host cell toxicity, and skin and pulmonary inflammations, 
however, to the best of our knowledge, the exact contribution of EVs during 
infection remains unclear. The study of EV-free S. aureus strains in the infection 
context could reveal valuable clues to their real contribution to pathogenesis. 
Nevertheless, to the present, this phenomenon is unknown. Finally, their ability 
to induce a host immune response has arisen interest in using EVs as vehicles for 
vaccination. Several studies reported that administration of S. aureus EVs induce 
protection against systemic, pulmonary, and cutaneous infections. Although 
being a recent field of study, these promising data sheds light onto the possible 
application of engineered EVs to prevent diseases caused by this important human 
pathogen.
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